FUJIFILM Irvine Scientific introduces BalanCD Gal Supplement for biotherapeutic development

FUJIFILM Irvine Scientific, Inc., a world leader in the optimization, development and manufacture of cell culture media and industrial cell culture solutions, today introduced BalanCD Gal Supplement. The new formula has been developed to increase galactosylation in biotherapeutic development, to help achieve desired glycan profiles for improved product quality and antibody efficacy.

FUJIFILM Irvine Scientific introduces BalanCD Gal Supplement for biotherapeutic development

Glycosylation is a critical aspect in development and optimization of protein-based therapeutics. The type and level of glycosylation can significantly affect antibody binding, function, and therapeutic efficacy. Galactosylation (the glycosylation of galactose) is a key method for controlling product quality due to the significant impact it has on antibody function, and the ability to control levels of galactosylation through the cell culture medium.

BalanCD Gal Supplement is a chemically-defined, animal component-free formula designed to increase N-linked galactosylation with a scalable protocol, offering researchers a simple method to control the process through the cell culture medium. The supplement is effective at low concentrations and is compatible with any basal growth medium.

BalanCD Gal Supplement has been developed as part of the BalanCD CHO media platform - an extended portfolio of chemically-defined, animal component-free growth and feed media formulated using Rational Culture Media Design. This multidimensional approach uses sequential, complementary development methods to leverage FUJIFILM Irvine Scientific scientists’ expertise in the effects of components and process parameters. The result is a media platform that delivers the precise combination of nutrients to maximize productivity, growth, and viability of CHO cell lines.

The BalanCD Gal Supplement has been designed to incorporate seamlessly into our BalanCD media portfolio, providing researchers in biotherapeutic development with a holistic, efficient growth and production platform. Developed by our expert research and development group, the new supplement supports scientists in streamlining workflows, ultimately to advance emerging therapies."

Robert Newman PhD, Chief Scientific Officer, FUJIFILM Irvine Scientific.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    FUJIFILM Irvine Scientific. (2019, September 11). FUJIFILM Irvine Scientific introduces BalanCD Gal Supplement for biotherapeutic development. News-Medical. Retrieved on October 03, 2024 from https://www.news-medical.net/news/20190911/FUJIFILM-Irvine-Scientific-introduces-BalanCD-Gal-Supplement-for-biotherapeutic-development.aspx.

  • MLA

    FUJIFILM Irvine Scientific. "FUJIFILM Irvine Scientific introduces BalanCD Gal Supplement for biotherapeutic development". News-Medical. 03 October 2024. <https://www.news-medical.net/news/20190911/FUJIFILM-Irvine-Scientific-introduces-BalanCD-Gal-Supplement-for-biotherapeutic-development.aspx>.

  • Chicago

    FUJIFILM Irvine Scientific. "FUJIFILM Irvine Scientific introduces BalanCD Gal Supplement for biotherapeutic development". News-Medical. https://www.news-medical.net/news/20190911/FUJIFILM-Irvine-Scientific-introduces-BalanCD-Gal-Supplement-for-biotherapeutic-development.aspx. (accessed October 03, 2024).

  • Harvard

    FUJIFILM Irvine Scientific. 2019. FUJIFILM Irvine Scientific introduces BalanCD Gal Supplement for biotherapeutic development. News-Medical, viewed 03 October 2024, https://www.news-medical.net/news/20190911/FUJIFILM-Irvine-Scientific-introduces-BalanCD-Gal-Supplement-for-biotherapeutic-development.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New insect medium delivers high viable cell density growth and protein yield